Treatment of Ph+ CML and ALL has dramatically changed since the advent of targeted therapy against the Bcr-Abl fusion protein at the turn of the twenty-first century, and so the prognosis has done. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.